Basics of Chimeric Antigen Receptor CAR Immunotherapy

Basics of Chimeric Antigen Receptor  CAR  Immunotherapy
Author: Mumtaz Y. Balkhi
Publsiher: Academic Press
Total Pages: 92
Release: 2019-07-31
ISBN 10: 0128197471
ISBN 13: 9780128197479
Language: EN, FR, DE, ES & NL

Basics of Chimeric Antigen Receptor CAR Immunotherapy Book Review:

Basics of Chimeric Antigen Receptor (CAR) Immunotherapy presents the latest on how T cell adoptive immunotherapy has progressed in its ultimate goal of curing metastatic malignant cancers. Recent clinical data obtained with checkpoint receptor blockade inhibitors and chimeric antigen receptor (CAR) therapy has been especially promising, thus generating renewed hope that we may be on the verge of finally curing cancer. Over the years, huge progress has been made in controlling several stage IV metastasized cancers through the clinical application of checkpoint receptor inhibitory drugs and CAR-Therapy that has seen unprecedented interest in the immunotherapy field. Presents the first book to provide a basic understanding of chimeric antigen receptor (CARs) design, production and clinical application protocols Provides unique authority as the editor has worked directly with CARs Discusses the challenges encountered in actual clinical trials and how these challenges can be overcome Includes a full chapter on various challenges researchers should expect to encounter in the CAR-therapy field

Chimeric Antigen Receptor T Cell Therapies for Cancer E Book

Chimeric Antigen Receptor T Cell Therapies for Cancer E Book
Author: Daniel W. Lee,Nirali N. Shah
Publsiher: Elsevier Health Sciences
Total Pages: 244
Release: 2019-11-30
ISBN 10: 0323755976
ISBN 13: 9780323755979
Language: EN, FR, DE, ES & NL

Chimeric Antigen Receptor T Cell Therapies for Cancer E Book Book Review:

From patient referral to post-therapy management, Chimeric Antigen Receptor (CAR) T-Cell Therapies for Cancer: A Practical Guide presents a comprehensive view of CAR modified T-cells in a concise and practical format. Providing authoritative guidance on the implementation and management of CAR T-cell therapy from Drs. Daniel W. Lee and Nirali N. Shah, this clinical resource keeps you up to date on the latest developments in this rapidly evolving area. Covers all clinical aspects, including patient referral, toxicities management, comorbidities, bridging therapy, post-CAR monitoring, and multidisciplinary approaches to supportive care. Includes key topics on associated toxicities such as predictive biomarkers, infections, and multidisciplinary approaches to supportive care. Presents current knowledge on FDA approved CAR T-cell products as well as developments on the horizon. Editors and authors represent leading investigators in academia and worldwide pioneers of CAR therapy.

Part I Understanding Cancer Immunotherapy A brief Review Part II What is Chimeric Antigen Receptor CAR T Cell Therapy An Emerging Cancer Treatment Modality

Part I  Understanding Cancer Immunotherapy  A brief Review  Part II     What is Chimeric Antigen Receptor  CAR  T  Cell Therapy     An Emerging Cancer Treatment Modality
Author: Dr. Hakim Saboowala
Publsiher: Dr.Hakim Saboowala
Total Pages: 135
Release: 2020-05-12
ISBN 10: 1928374650XXX
ISBN 13: 9182736450XXX
Language: EN, FR, DE, ES & NL

Part I Understanding Cancer Immunotherapy A brief Review Part II What is Chimeric Antigen Receptor CAR T Cell Therapy An Emerging Cancer Treatment Modality Book Review:

Part I- Understanding Cancer Immunotherapy: A brief Review. Immunotherapy, also called biologic therapy, is a type of cancer treatment that boosts the body's natural defenses to fight cancer. It uses substances made by the body or in a laboratory to improve or restore immune system function. Immunotherapy may work by: Stopping or slowing the growth of cancer cells Stopping cancer from spreading to other parts of the body Helping the immune system work better at destroying cancer cells There are several types of immunotherapy, including: Monoclonal antibodies and tumor-agnostic therapies Non-specific immunotherapies Oncolytic virus therapy T-cell therapy Cancer vaccines Part II- “What is Chimeric Antigen Receptor (CAR) T- Cell Therapy?” An Emerging Cancer Treatment Modality. Chimeric antigen receptor (CAR) T-cell therapy is an emerging cancer treatment modality in which the patients’ own immune cells are collected, genetically engineered to recognize a tumor-related target, expanded in vitro, and then reinfused to produce responses and prevent progression in a variety of malignancies (ie, adoptive cell transfer) Several types of adoptive cell transfer(ACT) are under investigation, but CAR T-cell therapy is the first to enter clinical practice. Like other technologies, CAR-T cell therapy has undergone a long development process in the past. Chimeric antigen receptor- (CAR-) T cell therapy is one of the most recent innovative immunotherapies and is rapidly evolving. At present, CAR-T cell therapy is developing rapidly, and many clinical trials have been established on a global scale, which has great commercial potential. I have endeavored to compile this E- Booklet into Two Parts i.e. Part I & Part II for better understanding of Chimeric antigen receptor (CAR) T-cell therapy, an emerging cancer treatment modality. In Part I, an effort has been made to describe Cancer Immunotherapy briefly whereas in Part II know about of CAR T-Cell Therapy-the first to enter clinical practice- has been embodied. Further it is attempted to describe toxicity of CAR-T cell therapy briefly and future development and opportunities for immunotherapy. …Dr. H. K. Saboowala. M.B.(Bom) .M.R.S.H.(London)

Chimeric Antigen Receptor T Cells

Chimeric Antigen Receptor T Cells
Author: Kamilla Swiech,Kelen Cristina Ribeiro Malmegrim,Virgínia Picanço-Castro
Publsiher: Humana
Total Pages: 274
Release: 2020-11-24
ISBN 10: 9781071601488
ISBN 13: 1071601482
Language: EN, FR, DE, ES & NL

Chimeric Antigen Receptor T Cells Book Review:

This volume provides comprehensive methods from expert scientists working in the Chimeric Antigen Receptor T Cell (CAR-T Cell) field. Chapters guide readers through the state-of-art of CAR-T cell technology, CAR design and vector production, CAR-T cell generation and manufacturing, CAR-T cell characterization, and quality control. Written in the highly successful Methods in Molecular Biology series format, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and tips on troubleshooting and avoiding known pitfalls. Authoritative and cutting-edge, Chimeric Antigen Receptor T Cells: Development and Production aims to be useful in the production of CAR-T cells, especially for therapeutic purposes.

Developing Costimulatory Molecules for Immunotherapy of Diseases

Developing Costimulatory Molecules for Immunotherapy of Diseases
Author: Manzoor Ahmad Mir
Publsiher: Academic Press
Total Pages: 322
Release: 2015-05-25
ISBN 10: 0128026758
ISBN 13: 9780128026755
Language: EN, FR, DE, ES & NL

Developing Costimulatory Molecules for Immunotherapy of Diseases Book Review:

Developing Costimulatory Molecules for Immunotherapy of Diseases highlights the novel concept of reverse costimulation and how it can be effectively exploited to develop immunotherapy using either humanized antibodies against CD80, CD86, and other costimulatory molecules or CD28 fusinogenic proteins in the treatment of diseases, including allergies, asthma, rheumatoid arthritis, multiple sclerosis, lupus nephritis, severe psoriasis, vulgaris tuberculosis, thopoid, transplantation therapeutic, cancer, and inflammation. The text aims to provide the latest information on the complex roles and interactions within the CD28 and B7 costimulatory families, with the hope that targeting these families will yield new therapies for the treatment of inflammation, autoimmunity, transplantation, cancer, and other infectious diseases. Highlights the novel concept of reverse costimulation and how it can be effectively exploited to develop immunotherapy Provides the latest information on the complex roles and interactions within the CD28 and B7 costimulatory families Targets new therapies for the treatment of inflammation, autoimmunity, transplantation, cancer, and other infectious diseases

Fast Facts CAR T Cell Therapy

Fast Facts  CAR T Cell Therapy
Author: R.J. Buka,A.J. Kansagra
Publsiher: Karger Medical and Scientific Publishers
Total Pages: 72
Release: 2021-01-26
ISBN 10: 3318067423
ISBN 13: 9783318067422
Language: EN, FR, DE, ES & NL

Fast Facts CAR T Cell Therapy Book Review:

Chimeric antigen receptor (CAR) T cells are genetically engineered immune cells that can seek out and destroy cancer cells. The results from their use in cancer immunotherapy have been very promising, but treatment is often associated with frequent, serious short-term toxicities. 'Fast Facts: CAR-T Therapy' explains what CAR T cells are and how they were developed, discusses the results of clinical trials and the management of toxicities, and outlines future improvements and applications. It is ideal reading for any healthcare professional wanting to know more about this exciting therapeutic field. Table of Contents: • CAR T cells • Clinical application • Practical aspects • Future directions

Chimeric Antigen Receptor CAR T cell Immunotherapy for MUC1 positive Breast Cancer

Chimeric Antigen Receptor  CAR  T cell Immunotherapy for MUC1 positive Breast Cancer
Author: Artemis Gavriil
Publsiher: Unknown
Total Pages: 135
Release: 2018
ISBN 10: 1928374650XXX
ISBN 13: OCLC:1063625133
Language: EN, FR, DE, ES & NL

Chimeric Antigen Receptor CAR T cell Immunotherapy for MUC1 positive Breast Cancer Book Review:

Defining Optimal T Cell Characteristics for Pediatric Chimeric Antigen Receptor CAR T Cell Trials

Defining Optimal T Cell Characteristics for Pediatric Chimeric Antigen Receptor  CAR  T Cell Trials
Author: Julie M. Rivers
Publsiher: Unknown
Total Pages: 23
Release: 2017
ISBN 10: 1928374650XXX
ISBN 13: OCLC:1004566387
Language: EN, FR, DE, ES & NL

Defining Optimal T Cell Characteristics for Pediatric Chimeric Antigen Receptor CAR T Cell Trials Book Review:

Background: Engineered chimeric antigen receptor (CAR) T cells have emerged as a powerful, highly personalized immunotherapy in pediatric cancer. Early phase clinical trials using CAR T cells targeting CD19 have resulted in complete response (CR) rates as high as 93% in children with relapsed and refractory acute lymphoblastic leukemia (ALL). Despite this success, there are many challenges that must be overcome before CAR T cell therapy can be used routinely in pediatric ALL or other malignancies. Objective: To develop novel biomarkers that will identify patients at high risk for poor product expansion, treatment failure and/or toxicity with current immunotherapy protocols and that may ultimately help improve manufacturing methods to produce safer and more effective CAR T cells. Design/Methods: Using flow cytometry, we evaluated T cell characteristics (memory phenotype, cytokine production, presence of markers of activation/exhaustion) of starting products in 43 patients enrolled and treated in a Phase I clinical trial, PLAT-02. Potential predictors of poor product expansion were assessed using the Wilcoxon Rank Sum Test. Results: A higher percentage of cells producing cytokines and expressing PD-1 in CD4 starting products was associated with poor expansion. Poor expansion was not associated with patient toxicities or outcomes. Discussion: Increased cytokine production and PD-1 expression suggest a more differentiated, effector-like phenotype of starting products that subsequently experience poor expansion, consistent with preclinical data, although numbers are limited. Conclusion: Ongoing correlative biology studies will be important in future immunotherapy trials as we seek to identify biomarkers that predict product expansion, toxicities and outcomes.

Translational Immunotherapy of Brain Tumors

Translational Immunotherapy of Brain Tumors
Author: John H. Sampson
Publsiher: Academic Press
Total Pages: 404
Release: 2017-02-06
ISBN 10: 0128026251
ISBN 13: 9780128026250
Language: EN, FR, DE, ES & NL

Translational Immunotherapy of Brain Tumors Book Review:

Translational Immunotherapy of Brain Tumors gives researchers and practitioners an up-to-date and comprehensive overview of the field. Chapters include adoptive immunotherapy, immunosuppression, CAR therapy of brain tumors, and dendritic cell therapy for brain tumors. Very few agents have been shown to be efficacious in the treatment of malignant gliomas. Recently, there have been a number of studies demonstrating the potential success of immunotherapy for brain tumors. Immunotherapeutics are becoming the most frequent drugs to be used in cancer therapy. These new breakthroughs, now approved by the FDA, are a part of multiple phase III international trials and ongoing research in malignant glioma, meaning that the information in this cutting-edge book will be of great importance to practitioners and researchers alike. Comprehensive overview, providing an update on immunology, translational immunotherapy, and clinical trials relating to malignant gliomas Edited by a prominent neurosurgeon with contributions by leading researchers in the field Ideal resource for researchers and practitioners interested in learning about mechanisms that use the immune system to treat brain tumors

Immunotherapy

Immunotherapy
Author: Krassimir Metodiev
Publsiher: BoD – Books on Demand
Total Pages: 414
Release: 2017-04-26
ISBN 10: 9535131052
ISBN 13: 9789535131052
Language: EN, FR, DE, ES & NL

Immunotherapy Book Review:

This is another attempt of InTechOpen to continue the dissemination of international knowledge and experience in the field of immunology. The present book includes a number of modern concepts of specialists and experts in the field of immunotherapy, covering the major topics and analyzing the history, current stage, and future ideas of application of modern immunomodulation. It is always a benefit, but also a compliment, to gather a team of internationally distinguished authors and to motivate them to reveal their expertise for the benefit of medical science and health practice. On behalf of all readers, immunologists, immunogeneticists, biologists, oncologists, microbiologists, virologists, hematologists, chemotherapists, health-care experts, as well as students and medical specialists, also on my personal behalf, I would like to extend my gratitude and highest appreciation to InTechOpen for giving me the unique chance to be the editor of this exclusive book.

Stem Cells From Hype to Real Hope

Stem Cells     From Hype to Real Hope
Author: Khawaja Husnain Haider,Salim Aziz, MD
Publsiher: Walter de Gruyter GmbH & Co KG
Total Pages: 220
Release: 2018-12-17
ISBN 10: 3110586916
ISBN 13: 9783110586916
Language: EN, FR, DE, ES & NL

Stem Cells From Hype to Real Hope Book Review:

This book is a compilation of the bench experience of leading experts from various research labs involved in the cutting edge area of research. The authors describe the use of stem cells both as part of the combinatorial therapeutic intervention approach and as tools (disease model) during drug development, highlighting the shift from a conventional symptomatic treatment strategy to addressing the root cause of the disease process. The book is a continuum of the previously published book entitled "Stem Cells: from Drug to Drug Discovery" which was published in 2017.

Cellular Therapies in Cancer

Cellular Therapies in Cancer
Author: Katy Rezvani,Rohtesh S. Mehta
Publsiher: Frontiers Media SA
Total Pages: 135
Release: 2020-01-16
ISBN 10: 2889633780
ISBN 13: 9782889633784
Language: EN, FR, DE, ES & NL

Cellular Therapies in Cancer Book Review:

T Cell Clones

T Cell Clones
Author: Harald von Boehmer,Werner Haas
Publsiher: Elsevier Science Limited
Total Pages: 339
Release: 1985
ISBN 10: 1928374650XXX
ISBN 13: UOM:39015009558340
Language: EN, FR, DE, ES & NL

T Cell Clones Book Review:

CAR T Cell Therapies for Non Hematopoietic Malignancies Taking Off The Training Wheels

CAR T Cell Therapies for Non Hematopoietic Malignancies  Taking Off The Training Wheels
Author: Avery Dexter Posey, Jr.,John - Maher,Marcela V. Maus
Publsiher: Frontiers Media SA
Total Pages: 135
Release: 2020-04-24
ISBN 10: 2889636879
ISBN 13: 9782889636877
Language: EN, FR, DE, ES & NL

CAR T Cell Therapies for Non Hematopoietic Malignancies Taking Off The Training Wheels Book Review:

Chimeric antigen receptor (CAR) T cell therapies for leukemia (e.g. tisagenlecleucel) and lymphoma (e.g. axicabtagene ciloleucel) have recently received regulatory approval in the United States. Phase I/II trials have demonstrated complete remission of refractory or relapsed tumors in 50% - 94% patients. However, the clinical successes of engineered T cells for the treatment of solid malignancies have thus far been few and far between. Furthermore, several instances of severe and lethal toxicities have arisen due to on-target, off-tumor recognition of antigen by T cell products. Recent advances in phase I trials for solid tumors, as well as in pre-clinical models, have revealed several variables that will be important to consider for the successful use of CAR-T cells in treating solid tumors. These variables include (i) regional versus systemic delivery; (ii) scFv versus ligand interactions; (iii) antigen loss versus escape; (iv) epitope spreading and (v) checkpoint expression on immune cells or tumor cells. Also, there remains outstanding mechanistic questions related to why differences exist in the persistence and tonic signaling of second-generation CD28 versus 4-1BB co-stimulated CAR-T cells. In addition, we are now learning the roles of lympho-depleting regimens (and associated toxicities) in modifying the persistence of engineered T cell therapies. A more comprehensive view of CAR-T cell strategies and important advances, both of pre-clinical and clinical evaluations, in solid tumors is necessary to drive these therapies forward.

Gene Therapy for Cancer

Gene Therapy for Cancer
Author: Kelly K. Hunt,Stephan A. Vorburger,Stephen G. Swisher
Publsiher: Springer Science & Business Media
Total Pages: 469
Release: 2007-10-26
ISBN 10: 159745222X
ISBN 13: 9781597452229
Language: EN, FR, DE, ES & NL

Gene Therapy for Cancer Book Review:

The three sections of this volume present currently available cancer gene therapy techniques. Part I describes the various aspects of gene delivery. In Part II, the contributors discuss strategies and targets for the treatment of cancer. Finally, in Part III, experts discuss the difficulties inherent in bringing gene therapy treatment for cancer to the clinic. This book will prove valuable as the volume of preclinical and clinical data continues to increase.

Practical Transfusion Medicine

Practical Transfusion Medicine
Author: Michael F. Murphy,Derwood H. Pamphilon
Publsiher: John Wiley & Sons
Total Pages: 576
Release: 2013-07-03
ISBN 10: 1118702999
ISBN 13: 9781118702994
Language: EN, FR, DE, ES & NL

Practical Transfusion Medicine Book Review:

This new edition of the comprehensive guide to transfusion medicine is now fully revised and updated. The Third Edition includes two new sections, one on alternatives to blood transfusion, and one on cellular and tissues therapy and organ transplantation. It focuses on clinical aspects but also covers background science and organizational issues. This timely volume highlights controversial issues and provides advice for everyday clinical questions in transfusion medicine. Practical Transfusion Medicine, Third Edition, is an essential manual for all those working in modern transfusion medicine.

Developments in T Cell Based Cancer Immunotherapies

Developments in T Cell Based Cancer Immunotherapies
Author: Paolo A. Ascierto,David F. Stroncek,Ena Wang
Publsiher: Humana Press
Total Pages: 305
Release: 2015-11-26
ISBN 10: 3319211676
ISBN 13: 9783319211671
Language: EN, FR, DE, ES & NL

Developments in T Cell Based Cancer Immunotherapies Book Review:

This volume illustrates the salient aspects of cancer biology relevant to the successful implementation of immunotherapy. Topics include enhancement of antigen-specific immune responses by anti-cancer vaccines, modulation of the function of T cells within the tumor microenvironment, and the effects of genetic, epigenetic, developmental, and environmental determinants on T cell function. Other topics covered include the ex vivo expansion of T or other immune cells and their genetic modification or reprogramming to increase their ability to survive and expand when adoptively transferred back to the patients. Specific attention is devoted to the genetic manipulation of T cells through the introduction of re-directed T cell receptors, chimeric antibody receptors, and other genetic manipulation aimed at improving their effectiveness as anti-cancer agents. Furthermore, the revolutionary role of checkpoint inhibitors and their potential in combination with other immunotherapeutic approaches or with standard chemo and radiation therapy are extensively discussed.

Gene Therapy of Cancer

Gene Therapy of Cancer
Author: Stanton L. Gerson,Edmund C. Lattime
Publsiher: Elsevier
Total Pages: 534
Release: 2002-04-04
ISBN 10: 9780080491363
ISBN 13: 0080491367
Language: EN, FR, DE, ES & NL

Gene Therapy of Cancer Book Review:

The Second Edition of Gene Therapy of Cancer provides crucial updates on the basic science and ongoing research in this field, examining the state of the art technology in gene therapy and its therapeutic applications to the treatment of cancer. The clinical chapters are improved to include new areas of research and more successful trials. Chapters emphasize the scientific basis of gene therapy using immune, oncogene, antisense, pro-drug activating, and drug resistance gene targets, while other chapters discuss therapeutic approaches and clinical applications. This book is a valuable reference for anyone needing to stay abreast of the latest advances in gene therapy treatment for cancer. Key Features * Provides in-depth description of targeted systems and treatment strategies * Explains the underlying cancer biology necessary for understanding a given therapeutic approach * Extensively covers immune therapeutics of vaccines, cytokines, and peptide-induced responses * Presents translational focus with emphasis on requirements for clinical implementation * Incorporates detailed illustrations of vectors and therapeutic approaches ideal for classroom presentations and general reference

Tumor Microenvironment

Tumor Microenvironment
Author: Peter P. Lee,Francesco M. Marincola
Publsiher: Springer Nature
Total Pages: 326
Release: 2020-03-25
ISBN 10: 303038862X
ISBN 13: 9783030388621
Language: EN, FR, DE, ES & NL

Tumor Microenvironment Book Review:

This book addresses the biological processes relevant to the immune phenotypes of cancer and their significance for immune responsiveness, based on the premise that malignant cells manipulate their surroundings through an evolutionary process that is controlled by interactions with innate immune sensors as well as the adaptive recognition of self/non-self. Checkpoint inhibitor therapy is now an accepted new form of cancer treatment. Other immuno-oncology approaches, such as adoptive cell therapy and metabolic inhibitors, have also shown promising results for specific indications. Immune resistance is common, however, limiting the efficacy of immunotherapy in many common cancer types. The reasons for such resistance are diverse and peculiar to the immune landscapes of individual cancers, and to the treatment modality used. Accordingly, approaches to circumvent resistance need to take into account context-specific genetic, biological and environmental factors that may affect the cancer immune cycle, and which can best be understood by studying the target tissue and correlated systemic immune markers. Understanding the major requirements for the evolutionary process governing human cancer growth in the immune-competent host will guide effective therapeutic choices that are tailored to the biology of individual cancers.

Cancer Immunotherapy Principles and Practice

Cancer Immunotherapy Principles and Practice
Author: Lisa H. Butterfield, PhD,Howard L. Kaufman, MD, FACS,Francesco M. Marincola, MD, FACS
Publsiher: Springer Publishing Company
Total Pages: 920
Release: 2017-06-28
ISBN 10: 1617052736
ISBN 13: 9781617052736
Language: EN, FR, DE, ES & NL

Cancer Immunotherapy Principles and Practice Book Review:

Cancer Immunotherapy Principles and Practice, from the Society of Immunotherapy of Cancer (SITC), is the authoritative reference on cancer immunobiology and the immunotherapy treatments that harness the immune system to combat malignant disease. Featuring five sections and over 50 chapters covering the Basic Principles of Tumor Immunology, Cancer Immunotherapy Targets and Classes, Immune Function in Cancer Patients, Disease Specific Treatments and Outcomes, and Regulatory Aspects of Cancer Immunotherapy, this book covers all major topics that have shaped the development of immunotherapy and propelled it to its current place at the forefront of cancer treatment innovation. This volume is a comprehensive resource for oncologists and fellows, immunologists, cancer researchers, and related practitioners seeking understanding of the basic science and clinical applications of cancer immunotherapy. As well as presenting the evidence for immune-based cancer treatment, it positions immunotherapy in the context of other available cancer treatments and provides data on response rates, risks, and toxicities across a variety of diseases. Filled with detailed tables, and instructive illustrations, as well as key points for quick reference, Cancer Immunotherapy Principles and Practice simplifies a challenging and dynamic subject. Key Features: Clearly summarizes the basic principles and research supporting cancer immunotherapy clinical translation Contains expert guidance and treatment strategies for all immunotherapy classes and agents, including cell-based therapies, monoclonal antibodies, cytokine therapies, checkpoint inhibitors, oncolytic viruses, adjuvant approaches, and treatment combinations Includes expert perspectives from leading authorities in the field Provides information on all FDA-approved immunotherapies, including clinical management and outcome data Discusses clinical aspects of immunotherapy for individual cancer types, including melanoma and other skin cancers, lung cancers, gynecologic cancers, gastrointestinal cancers, hematologic cancers, genitourinary cancers, head and neck cancers, sarcomas, brain and other CNS cancers, breast cancer, and pediatric malignancies. Explains regulatory aspects behind the development and approval of immunotherapy drugs Includes Online Access to the Digital Book